Kestra Medical Technologies (KMTS) Common Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Common Equity data on file, last reported at $288.0 million in Q1 2026.

• Quarterly Common Equity rose 211.67% year-over-year to $288.0 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $288.0 million (up 211.67% YoY) and the FY2025 annual result came in at $205.4 million, up 198.1% from the prior year.
• Common Equity rose to $288.0 million in Q1 2026 per KMTS's latest filing, from $164.1 million in the prior quarter.
• Across five years, Common Equity topped out at $288.0 million in Q1 2026 and bottomed at -$257.9 million in Q1 2025.
• The 3-year median for Common Equity is $164.1 million (2025), against an average of $13.1 million.
• The widest annual swing landed in 2025, when Common Equity plunged 230.96%; it then surged 211.67% in 2026.
• Tracing KMTS's Common Equity over 3 years: stood at -$236.5 million in 2024, then surged by 169.37% to $164.1 million in 2025, then surged by 75.52% to $288.0 million in 2026.
• Per Business Quant, the three latest KMTS Common Equity figures stand at $288.0 million (Q1 2026), $164.1 million (Q4 2025), and $184.2 million (Q3 2025).

Peer Comparison